|
Sex (male vs female)
|
0.98 (0.89–1.07)
|
|
Age (65 ≤ age < 75 vs age <65)
|
1.71 (1.5–1.96)***
|
|
Age (age ≥75 vs age <65)
|
2.51 (2.2–2.85)***
|
|
Hypertension (yes vs no)
|
1.2 (1.06–1.37)**
|
|
Peripheral vascular disease (yes vs no)
|
1.57 (1.34–1.84)***
|
|
Heart failure (yes vs no)
|
1.35 (1.23–1.49)***
|
|
End stage renal disease (yes vs no)
|
1.76 (1.51–2.06)***
|
|
Cerebrovascular disease (yes vs no)
|
1.33 (1.21–1.47)***
|
|
Chronic obstructive pulmonary disease (yes vs no)
|
1.33 (1.16–1.52)***
|
|
Percutaneous coronary intervention (yes vs no)
|
0.54 (0.49–0.6)***
|
|
Any antiplatelet (yes vs no)
|
0.58 (0.49–0.7)***
|
|
ACEI or ARB (yes vs no)
|
0.72 (0.65–0.8)***
|
|
β-Blocker (yes vs no)
|
0.79 (0.71–0.87)***
|
|
Heparin or low molecular weight heparin (yes vs no)
|
1.02 (0.91–1.15)
|
|
α-Glucosidase (yes vs no)
|
0.95 (0.83–1.08)
|
|
Glinides (yes vs no)
|
1.05 (0.94–1.18)
|
|
Metformin (yes vs no)
|
0.77 (0.68–0.86)***
|
|
Sulfonylureas (yes vs no)
|
0.91 (0.82–1.01)
|
|
Thiazolidinedione (yes vs no)
|
0.79 (0.59–1.04)
|
|
DPP-4 inhibitor (yes vs no)
|
0.86 (0.78–0.95)**
|
